Skip to main content

Advertisement

SpringerLink
Log in

Olanzapine compared to quetiapine in adolescents with a first psychotic episode

  • ORIGINAL CONTRIBUTION
  • Published:
European Child & Adolescent Psychiatry Aims and scope Submit manuscript

Abstract

Objective

To compare the efficacy, safety, and tolerability of olanzapine and quetiapine in adolescents with first episode psychosis.

Method

Fifty adolescents (age 16 ± 1.25) with a first episode of psychosis were randomized to quetiapine or olanzapine in a 6-month open label study. Efficacy and side effect scales, as well as vital signs and laboratory data were recorded at baseline, 7, 15, 30, 90, and 180 days (end of study).

Results

Out of the total sample included in the study, 32 patients completed the trial (quetiapine n = 16, olanzapine n = 16). Patients in both treatment groups had a significant reduction in all clinical scales with the exception of the negative scale of the Positive and Negative Symptom Scale (PANSS) for olanzapine and the general psychopathology scale of the PANSS for quetiapine. The only difference between treatment arms on the clinical scales was observed on the patients’ strength and difficulties questionnaire (SDQ) scale, with greater improvement for olanzapine. Patients on olanzapine gained 15.5 kg and patients on quetiapine gained 5.5 kg.

Conclusion

Olanzapine and quetiapine reduced psychotic symptoms in this adolescent sample. Patients on olanzapine gained significantly more weight. Side effects with both drugs seemed to be more prevalent than those reported in adult studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Arango C, Parellada M, Moreno DM (2004) Clinical effectiveness of new generation antipsychotics in adolescent patients. Eur Neuropsychopharmacol 14:S471–S479

    Article  PubMed  CAS  Google Scholar 

  2. Barnes TR (2003) The Barnes Akathisia rating scale—revisited. J Psychopharmacol 17:365–370

    Article  PubMed  Google Scholar 

  3. Conley RR, Kelly DL (2005) Second-generation antipsychotics for schizophrenia: a review of clinical pharmacology and medication-associated side effects. Isr J Psychiatry Relat Sci 42:51–60

    PubMed  Google Scholar 

  4. Correll CU, Malhotra AK (2004) Pharmacogenetics of antipsychotic-induced weight gain. Psychopharmacology (Berl) 174:477–489

    Article  CAS  Google Scholar 

  5. Correll CU, Penzner JB, Parikh UH, Mughal T, Javed T, Carbon M, Malhotra AK (2006) Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatr Clin N Am 15:177–206

    Article  PubMed  Google Scholar 

  6. Charach A, Volpe T, Boydell KM, Gearing RE (2008) A theoretical approach to medication adherence for children and youth with psychiatric disorders. Harv Rev Psychiatry 16:126–135

    Article  PubMed  Google Scholar 

  7. Fedorowicz VJ, Fombonne E (2005) Metabolic side effects of atypical antipsychotics in children: a literature review. J Psychopharmacol 19:533–550

    Article  PubMed  CAS  Google Scholar 

  8. Findling RL (2005) Update on the treatment of bipolar disorder in children and adolescents. Eur Psychiatry 20:87–91

    Article  PubMed  Google Scholar 

  9. Findling RL, McNamara NK, Youngstrom EA, Branicky LA, Demeter CA, Schulz SC (2003) A prospective, open-label trial of olanzapine in adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry. 42:170–175

    Article  PubMed  Google Scholar 

  10. Fraguas D, Merchan-Naranjo J, Laita P, Parellada M, Moreno D, Ruiz-Sancho A, Cifuentes A, Giraldez M, Arango C (2008) Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. J Clin Psychiatry 69:1166–1175

    Article  PubMed  CAS  Google Scholar 

  11. Goodman R (1999) The extended version of the strengths and difficulties questionnaire as a guide to child psychiatric caseness and consequent burden. J Child Psychol Psychiatry 40:791–799

    Article  PubMed  CAS  Google Scholar 

  12. Goodman R (1997) The strengths and difficulties questionnaire: a research note. J Child Psychol Psychiatry 38:581–586

    Article  PubMed  CAS  Google Scholar 

  13. Gothelf D, Apter A, Reidman J, Brand-Gothelf A, Bloch Y, Gal G, Kikinzon L, Tyano S, Weizman R, Ratzoni G (2003) Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. J Neural Transm 110:545–560

    Article  PubMed  CAS  Google Scholar 

  14. Guy W (1976) Clinical Global Impression. ECDEU Assessment Manual for Psychopharmacology revised. National Institute of Mental Health, Rockville

    Google Scholar 

  15. Hamilton M (1967) Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278–296

    PubMed  CAS  Google Scholar 

  16. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW (2006) Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch Gen Psychiatry 63:1079–1087

    Article  PubMed  CAS  Google Scholar 

  17. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, Lopez-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rossler A, Grobbee DE (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371:1085–1097

    Article  PubMed  CAS  Google Scholar 

  18. Kay SR, Opler LA, Lindenmayer JP (1989) The positive and negative syndrome scale (PANSS): rationale and standardisation. Br J Psychiatry Suppl, pp 59–67

  19. Keefe RS, Sweeney JA, Gu H, Hamer RM, Perkins DO, McEvoy JP, Lieberman JA (2007) Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 164:1061–1071

    Article  PubMed  Google Scholar 

  20. Kopala LC, Good KP, Milliken H, Buiteman C, Woodley H, Rui Q, Whitehorn D, Love L, Balshaw R, Kiss I, Honer WG (2006) Treatment of a first episode of psychotic illness with quetiapine: an analysis of 2 year outcomes. Schizophr Res 81:29–39

    Article  PubMed  Google Scholar 

  21. Kumra S, Frazier JA, Jacobsen LK, McKenna K, Gordon CT, Lenane MC, Hamburger SD, Smith AK, Albus KE, Alaghband-Rad J, Rapoport JL (1996) Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 53:1090–1097

    PubMed  CAS  Google Scholar 

  22. Laita P, Cifuentes A, Doll A, Llorente C, Cortes I, Parellada M, Moreno D, Ruiz-Sancho A, Graell M, Arango C (2007) Antipsychotic-related abnormal involuntary movements and metabolic and endocrine side effects in children and adolescents. J Child Adolesc Psychopharmacol 17:487–502

    Article  PubMed  Google Scholar 

  23. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209–1223

    Article  PubMed  CAS  Google Scholar 

  24. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, Wei H, Hamer RM (2003) Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 160:1396–1404

    Article  PubMed  Google Scholar 

  25. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987) The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 334:1–100

    Article  PubMed  CAS  Google Scholar 

  26. McConville B, Carrero L, Sweitzer D, Potter L, Chaney R, Foster K, Sorter M, Friedman L, Browne K (2003) Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: an open-label extension trial. J Child Adolesc Psychopharmacol 13:75–82

    Article  PubMed  Google Scholar 

  27. McConville BJ, Arvanitis LA, Thyrum PT, Yeh C, Wilkinson LA, Chaney RO, Foster KD, Sorter MT, Friedman LM, Brown KL, Heubi JE (2000) Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders. J Clin Psychiatry 61:252–260

    PubMed  CAS  Google Scholar 

  28. Mozes T, Ebert T, Michal SE, Spivak B, Weizman A (2006) An Open-label randomized comparsion of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia. J Child Adolesc Psychopharmacol 16:393–403

    Article  PubMed  Google Scholar 

  29. Mozes T, Toren P, Chernauzan N, Mester R, Yoran-Hegesh R, Blumensohn R, Weizman A (1994) Clozapine treatment in very early onset schizophrenia. J Am Acad Child Adolesc Psychiatry 33:65–70

    Article  PubMed  CAS  Google Scholar 

  30. Naber D, Karow A, Lambert M (2005) Subjective well-being under the neuroleptic treatment and its relevance for compliance. Acta Psychiatr Scand Suppl, pp 29–34

  31. Naber D, Moritz S, Lambert M, Pajonk FG, Holzbach R, Mass R, Andresen B (2001) Improvement of schizophrenic patients’ subjective well-being under atypical antipsychotic drugs. Schizophr Res 50:79–88

    Article  PubMed  CAS  Google Scholar 

  32. Olfson M, Blanco C, Liu L, Moreno C, Laje G (2006) National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 63:679–685

    Article  PubMed  Google Scholar 

  33. Purdon SE, Snaterse M (1998) Selective serotonin reuptake inhibitor modulation of clozapine effects on cognition in schizophrenia. Can J Psychiatry 43:84–85

    PubMed  CAS  Google Scholar 

  34. Sengupta SM, Klink R, Stip E, Baptista T, Malla A, Joober R (2005) Weight gain and lipid metabolic abnormalities induced by olanzapine in first-episode, drug-naive patients with psychotic disorders. Schizophr Res 80:131–133

    Article  PubMed  Google Scholar 

  35. Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H, Aluwahlia S (1983) A children’s global assessment scale (CGAS). Arch Gen Psychiatry 40:1228–1231

    PubMed  CAS  Google Scholar 

  36. Shaw JA, Lewis JE, Pascal S, Sharma RK, Rodriguez RA, Guillen R, Pupo-Guillen M (2001) A study of quetiapine: efficacy and tolerability in psychotic adolescents. J Child Adolesc Psychopharmacol 11:415–424

    Article  PubMed  CAS  Google Scholar 

  37. Shaw P, Sporn A, Gogtay N, Overman GP, Greenstein D, Gochman P, Tossell JW, Lenane M, Rapoport JL (2006) Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry 63:721–730

    Article  PubMed  CAS  Google Scholar 

  38. Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA (2004) A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology 29:133–145

    Article  PubMed  CAS  Google Scholar 

  39. Simpson GM, Angus JW (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11–19

    Article  PubMed  CAS  Google Scholar 

  40. Velligan DI, Newcomer J, Pultz J, Csernansky J, Hoff AL, Mahurin R, Miller AL (2002) Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophr Res 53:239–248

    Article  PubMed  Google Scholar 

  41. Voruganti LP, Awad AG, Parker G, Forrest C, Usmani Y, Fernando ML, Senthilal S (2007) Cognition, functioning and quality of life in schizophrenia treatment: results of a one-year randomized controlled trial of olanzapine and quetiapine. Schizophr Res 96:146–155

    Article  PubMed  CAS  Google Scholar 

  42. Young RC, Biggs JT, Ziegler VE, Meyer DA (1978) A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 133:429–435

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by Supported by Investigator Initiated Study (D1441C00007) funded by AstraZeneca,, Fundación Alicia Koplowitz, and Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM.

Author information

Authors and Affiliations

  1. Psychiatry Department, Adolescent Unit, Hospital General Universitario Gregorio Marañón, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, C/Ibiza 43, 28009, Madrid, Spain

    Celso Arango MD, PhD, Olalla Robles PhD, Mara Parellada MD, PhD, Ana Ruiz-Sancho MD, Oscar Medina MD, Arantzazu Zabala PhD & Dolores Moreno MD, PhD

  2. Department of Psychiatry, Hospital Infanta Sofia, San Sebastian de los Reyes, Madrid, Spain

    David Fraguas MD

  3. Neurological Rehabilitation Center, Oviedo, Spain

    Igor Bombín PhD

Authors
  1. Celso Arango MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Olalla Robles PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mara Parellada MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. David Fraguas MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ana Ruiz-Sancho MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Oscar Medina MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Arantzazu Zabala PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Igor Bombín PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Dolores Moreno MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Celso Arango MD, PhD.

Additional information

Clinical Trials Registry:

Trial Registry name: Estudio piloto comparativo de quetiapina frente a olanzapina en pacientes con primeros brotes psicóticos de inicio en la infancia y la adolescencia.

URL: http://www.agemed.es/

Registration identification number: 02-0300, SPGM-001.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Arango, C., Robles, O., Parellada, M. et al. Olanzapine compared to quetiapine in adolescents with a first psychotic episode. Eur Child Adolesc Psychiatry 18, 418–428 (2009). https://doi.org/10.1007/s00787-009-0749-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00787-009-0749-5

Keywords

Search

Navigation